Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 4/20 | 0.52 |
| ▸ | CES2 | O00748 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3323928 | 1.00 | CES1 (0.52) | CES1CES2LMNAALDH1A1MAPK1 | |
| SCHEMBL3319972 | 1.00 | CES1 (0.52) | CES1CES2LMNAALDH1A1MAPK1 | |
| SCHEMBL7965904 | 0.83 | CES1 (0.48) | CES1CES2LMNAALDH1A1MAPK1 | |
| SCHEMBL7002681 | 0.81 | PDPK1 (0.52) | LMNAALDH1A1MAPK1HIF1ATDP1 | |
| SCHEMBL2985359 | 0.80 | CES1 (0.54) | CES1CES2LMNAALDH1A1MAPK1 | |
| SCHEMBL760303 | 0.80 | MAPK1 (0.52) | CES1CES2LMNAALDH1A1MAPK1 | |
| SCHEMBL16897736 | 0.80 | LMNA (0.42) | CES1CES2LMNAALDH1A1MAPK1 | |
| SCHEMBL11537696 | 0.79 | PARP1 (0.52) | LMNAALDH1A1HRH1KCNH2MAPT | |
| SCHEMBL5952562 | 0.78 | MAPK1 (0.50) | CES1CES2LMNAALDH1A1MAPK1 | |
| SCHEMBL8780874 | 0.78 | CES1 (0.52) | CES1CES2LMNAALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3266774-B1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AS PHOSPHATIDYLINOSITOL 3-KINASE DELTA INHIBITOR AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2019-09-04 | — | — | EP | disclosed |
| US-10077258-B2 | Substituted pyrimidine compounds as phosphatidylinositol 3-kinase delta inhibitor and use thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2018-09-18 | — | — | US | disclosed |
| US-20180037576-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AS PHOSPHATIDYLINOSITOL 3-KINASE DELTA INHIBITOR AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2018-02-08 | — | — | US | disclosed |
| EP-3266774-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AS PHOSPHATIDYLINOSITOL 3-KINASE DELTA INHIBITOR AND USE THEREOF | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2018-01-10 | — | — | EP | disclosed |
| US-20100125070-A1 | Bupropion Metabolites and Methods of Their Synthesis and Use | FANG KEVIN QUN | 2010-05-20 | — | — | US | disclosed |
| US-20060058300-A1 | Intermediates of bupropion metabolites synthesis | SEPRACOR INC. | 2006-03-16 | — | — | US | disclosed |
| EP-1165086-A4 | BUPROPION METABOLITES AND METHODS OF THEIR SYNTHESIS AND USE | SEPRACOR INC (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1602369-A2 | Bupropion Metabolites and Methods of their Synthesis and Use | Sepracor, Inc. (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1259243-A2 | BUPROPION METABOLITES AND METHODS OF THEIR SYNTHESIS AND USE | SEPRACOR, INC. (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020052341-A1 | Bupropion metabolites and methods of their synthesis and use | SEPRACOR INC. | 2002-05-02 | — | — | US | disclosed |
| EP-0038071-B1 | NEW UNLABELLED AND RADIOACTIVE LABELLED DERIVATIVES OF BUTYLAMINO PROPIOPHENONE, THEIR PREPARATION, IMMUNOGENS OBTAINED FROM THE UNLABELLED DERIVATIVES AND A PROCESS FOR IMMUNOGEN PREPARATION, ANTISERA RAISED USING THE IMMUNOGENS AND A METHOD FOR RAISING ANTISERA, A RADIOIMMUNOASSAY METHOD AND A TEST KIT FOR USE IN THE ASSAY METHOD | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-11-14 | — | — | EP | disclosed |
| US-4356165-A | Bupropion radioimmunoassay, and kit | BURROUGHS WELLCOME CO. (US) | 1982-10-26 | — | — | US | disclosed |
| US-4355179-A | Radioactive nuclide labeled propiophenone compounds | BURROUGHS WELLCOME CO. (US) | 1982-10-19 | — | — | US | disclosed |
| US-4347177-A | Compounds and methods of making them | BURROUGHS WELLCOME CO. (US) | 1982-08-31 | — | — | US | disclosed |
| US-4347382-A | 3H Labeled compounds | BURROUGHS WELLCOME CO. (US) | 1982-08-31 | — | — | US | disclosed |
| US-4347178-A | Compounds and methods of making | BURROUGHS WELLCOME CO. (US) | 1982-08-31 | — | — | US | disclosed |
| US-4347176-A | Compounds and methods of making same | BURROUGHS WELLCOME CO. (US) | 1982-08-31 | — | — | US | disclosed |
| EP-0038071-A2 | New unlabelled and radioactive labelled derivatives of butylamino propiophenone, their preparation, immunogens obtained from the unlabelled derivatives and a process for immunogen preparation, antisera raised using the immunogens and a method for raising antisera, a radioimmunoassay method and a test kit for use in the assay method | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-10-21 | — | — | EP | disclosed |
| US-4153707-A | Fungicidal isoxazolyl phenols and method of use | THE UPJOHN COMPANY (US) | 1979-05-08 | — | — | US | disclosed |
| US-4065574-A | New method for controlling fungi using 4-chromone, 4-chromanone, 4-chromone oxime and 4-chromanone oxime compounds | THE UPJOHN COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052341-A1 | Bupropion metabolites and methods of their synthesis and use | MAOB, MAOA, HTR5A | CES1 834/4885CES2 156/4885LMNA 3174/4885 |
| US-20060058300-A1 | Intermediates of bupropion metabolites synthesis | MAOB, MAOA, SLC18A2 | CES1 706/4885CES2 176/4885LMNA 3466/4885 |
| US-20180037576-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AS PHOSPHATIDYLINOSITOL 3-KINASE DELTA INHIBITOR AND USE THEREOF | PIK3CA, PIK3CD, PIK3CB | CES1 1345/4885CES2 3980/4885LMNA 2278/4885 |
| US-10077258-B2 | Substituted pyrimidine compounds as phosphatidylinositol 3-kinase delta inhibitor and use thereof | PIK3CA, PIK3CD, PIK3CB | CES1 1345/4885CES2 3980/4885LMNA 2278/4885 |
| US-20100125070-A1 | Bupropion Metabolites and Methods of Their Synthesis and Use | MAOB, MAOA, HTR5A | CES1 834/4885CES2 156/4885LMNA 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.